Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Cardiovascular Imaging Reports
Published in: Current Cardiovascular Imaging Reports 1/2016

01-01-2016 | Cardiac Nuclear Imaging (A Cuocolo, Section Editor)

Nuclear Cardiology in the Management of Patients with Heart Failure

Authors: Amalia Peix, Lázaro O. Cabrera, Kenia Padrón

Published in: Current Cardiovascular Imaging Reports | Issue 1/2016

Login to get access

Abstract

Heart failure is increasing worldwide, resulting in considerable disability, mortality, and high healthcare costs. Gated-SPECT or PET imaging is the most prominent imaging modality useful both for diagnosis and prognosis, capable of providing information about ventricular function, presence of intraventricular synchronism, and myocardial perfusion in the same test. In addition, PET can also offer quantification of coronary blood flow and metabolism. On the other hand, 123I- metaiodobenzylguanidine (MIBG) scintigraphy is the only imaging technique which provides information regarding the adrenergic function of the heart. This review provides an overview of the literature published over the past year relevant to this topic, presented in three parts: myocardial perfusion imaging, intraventricular synchronism assessment, and cardiac sympathetic innervation.
Literature
1.
Najafi F, Jamrozik K, Dobson AJ. Understanding the ‘epidemic of heart failure’: a systematic review of trends in determinants of heart failure. Eur J Heart Fail. 2009;11:472–9.CrossRefPubMed
2.
3.
Khatibzadeh S, Farzadfar F, Oliver J, Ezzati M, Moran A. Worldwide risk factors for heart failure: a systematic review and pooled analysis. Int J Cardiol. 2013;168:1186–94.PubMedCentralCrossRefPubMed
4.
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127:e6–245.CrossRefPubMed
5.
Mc Murray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–47.CrossRef
6.
International Atomic Energy Agency (IAEA). Nuclear Cardiology: guidance and recommendations for implementation in developing countries. IAEA Human Health Series No. 23 STI/PUB/1566. Vienna, Austria: IAEA; 2012.
7.•
Peix A, Mesquita CT, Paez D, Pereira CC, Felix R, Gutierrez C, et al. Nuclear medicine in the management of patients with heart failure: guidance from an expert panel of the International Atomic Energy Agency (IAEA). Nucl Med Commun. 2014;35:818–23. This IAEA guide is intended to reinforce the information on the use of nuclear cardiology techniques for the assessment of heart failure and associated myocardial disease.PubMedCentralPubMed
8.•
Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39:1151–8. Meta-analysis including 3 088 patients that demonstrated that patients with myocardial viability had a better outcome when revascularized than those without.CrossRefPubMed
9.
Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364:1617–25.PubMedCentralCrossRefPubMed
10.••
Bax JJ, Delgado V. Myocardial viability as integral part of the diagnostic and therapeutic approach to ischemic heart failure. J Nucl Cardiol. 2015;22:229–45. Careful and comprehensive analysis of myocardial viability as part of the complete assessment of ischemic heart failure to provide optimal and personalized therapy to these patients.PubMedCentralCrossRefPubMed
11.
Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M, et al. PARR-2 Investigators. F-18-fluorodeoxyglucose positron emission tomography imaging assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50:2002–12.CrossRefPubMed
12.
Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–619.CrossRefPubMed
13.
Mut F, Giubbini R, Vitola J, Lusa L, Sobic-Saranovic D, Peix A, et al. Detection of post-exercise stunning by early gated SPECT myocardial perfusion imaging: results from the IAEA multi-center study. J Nucl Cardiol. 2014;21:1168–76.CrossRefPubMed
14.
Stehlik J, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, et al. International Society of Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report–2012. J Heart Lung Transplant. 2012;31:1052–64.CrossRefPubMed
15.
Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. International Society of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29:914–56.CrossRefPubMed
16.
Pollack A, Nazif T, Mancini D, Weisz G. Detection and imaging of cardiac allograft vasculopathy. J Am Coll Cardiol Cardiovasc Imaging. 2013;6:613–23.CrossRef
17.
Mc Ardle BA, Davies RA, Chen L, Small GR, Ruddy TD, Dwivedi G, et al. Prognostic value of Rubidium-82 positron emission tomography in patients after heart transplant. Circ Cardiovasc Imaging. 2014;7:930–7.CrossRef
18.
19.
Mc Ardle BA, Leung E, Ohira H, Cocker MS, de Kemp RA, Da Silva J, et al. The role of F(18)-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis. J Nucl Cardiol. 2013;20:297–306.CrossRefPubMed
20.
21.
Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53:241–8.CrossRefPubMed
22.•
Jivraj N, Phinikaridou A, Shah AM, Botnar RM. Molecular imaging of myocardial infarction. Basic Res Cardiol. 2014;109(1):397. doi:10.​1007/​s00395-013-0397-2. Review of novel non-invasive imaging methods, using targeted imaging agents, which allow imaging of the molecular processes underlying the post-myocardial infarction immune cell response, and subsequent remodeling.CrossRefPubMed
23.
Majmudar MD, Murthy VL, Shah RV, Kolli S, Mousavi N, Foster CR. Quantification of coronary flow reserve in patients with ischaemic and non-ischaemic cardiomyopathy and its association with clinical outcomes. Eur Heart J Cardiovasc Imaging. 2015;16:900–9.CrossRefPubMed
24.••
Prior JO, Farhad H, Muller O. Multimodality imaging in ischemic cardiomyopathy. Curr Cardiovasc Imaging Rep. 2014;7:9285. Up-to-date comprehensive overview of cardiac multimodality imaging already in clinical use, as well as a combination of techniques with promising or developing applications.PubMedCentralCrossRefPubMed
25.
Flotats A, Knuuti J, Gutberlet M, Marcassa C, Bengel FM, Kaufmann PA, et al. Hybrid cardiac imaging: SPECT/CT and PET/CT. A joint position statement by the European Association of Nuclear Medicine (EANM), the European Society of Cardiac Radiology (ESCR) and the European Council of Nuclear Cardiology (ECNC). Eur J Nucl Med Mol Imaging. 2011;38:201–12.CrossRefPubMed
26.
Lin X, Xu H, Zhao X, Chen J. Sites of latest mechanical activation as assessed by SPECT myocardial perfusion imaging in ischemic and dilated cardiomyopathy patients with LBBB. Eur J Nucl Med Mol Imaging. 2014;41:1232–9.PubMedCentralCrossRefPubMed
27.
Bose A, Kandala J, Upadhyay GA, Riedl L, Ahmado I, Padmanabhan R, et al. Impact of myocardial viability and left ventricular lead location on clinical outcome in cardiac resynchronization therapy recipients with ischemic cardiomyopathy. J Cardiovasc Electrophysiol. 2014;25:507–13.CrossRefPubMed
28.
Botvinick EH, Badhwar N, O’Connell JW. Cardiac resynchronization therapy: the role of equilibrium radionuclide angiography. Medicamundi. 2008;52:51–8.
29.
Toussaint JF, Peix A, Lavergne T, Ponce F, Froissart M, Alonso C, et al. Reproducibility of the ventricular synchronization parameters assessed by multiharmonic phase analysis of radionuclide angiography in the normal heart. Int J Cardiovasc Imaging. 2002;18:187–94.CrossRefPubMed
30.
Lalonde M, Birnie D, Ruddy TD, de Kemp RA, Beanlands RS, Wassenaar R, et al. SPECT gated blood pool phase analysis of lateral wall motion for prediction of CRT response. Int J Cardiovasc Imaging. 2014;30:559–69.CrossRefPubMed
31.
Chen J, Garcia EV, Folks RD, Cooke CD, Faber TL, Tauxe EL, et al. Onset of left ventricular mechanical contraction as determined by phase analysis of ECG-gated myocardial perfusion SPECT imaging: development of a diagnostic tool for assessment of cardiac mechanical dyssynchrony. J Nucl Cardiol. 2005;12:687–95.CrossRefPubMed
32.
Zafrir N, Nevzorov R, Bental T, Strasberg B, Gutstein A, Mats I, et al. Prognostic value of left ventricular dyssynchrony by myocardial perfusion-gated SPECT in patients with normal and abnormal left ventricular functions. J Nucl Cardiol. 2014;21:532–40.CrossRefPubMed
33.
Hess PL, Shaw LK, Vemulapalli S, Pagnanelli R, O’Connor CM, Borges-Neto S. An alternative method to examine the predictive value of mechanical dyssynchrony. J Nucl Cardiol. 2015;22:686–9.CrossRefPubMed
34.
Borges-Neto S, Samad Z. In search of the perfect indicators of left ventricular mechanical dyssynchrony. J Nucl Cardiol. 2015;22:1259–61.CrossRefPubMed
35.
Romero-Farina G, Aguadé-Bruix S, Candell-Riera J, Pizzi MN, García-Dorado D. Cut-off values of myocardial perfusion gated-SPECT phase analysis parameters of normal subjects, and conduction and mechanical cardiac diseases. J Nucl Cardiol. 2015;22:1247–58.CrossRefPubMed
36.
Samad Z, Atchley A, Trimble M, Sun JL, Shaw LK, Pagnanelli R, et al. Prevalence and predictors of mechanical dyssynchrony as defined by phase analysis in patients with left ventricular dysfunction undergoing gated SPECT myocardial perfusion imaging. J Nucl Cardiol. 2011;18:24–30.PubMedCentralCrossRefPubMed
37.
Aljaroudi W, Koneru J, Heo J, Iskandrian AE. Impact of ischemia on left ventricular dyssynchrony by phase analysis of gated single photon emission computed tomography myocardial perfusion imaging. J Nucl Cardiol. 2011;18:36–42.CrossRefPubMed
38.
Chen CC, Shen TY, Chang MC, Hung GU, Chen WC, Kao CH, et al. Stress-induced myocardial ischemia is associated with early post-stress left ventricular mechanical dyssynchrony as assessed by phase analysis of 201Tl gated SPECT myocardial perfusion imaging. Eur J Nucl Med Mol Imaging. 2012;39:1904–9.PubMedCentralCrossRefPubMed
39.
Mukherjee A, Patel CD, Naik N, Sharma G, Roy A. Quantitative assessment of cardiac mechanical dyssynchrony and prediction of response to cardiac resynchronization therapy in patients with nonischaemic dilated cardiomyopathy using gated myocardial perfusion SPECT. Nucl Med Commun. 2015;36:494–501.PubMed
40.
Singh JP, Klein HU, Huang DT, Reek S, Kuniss M, Quesada A, et al. Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADITCRT) Trial. Circulation. 2011;123:1159–66.CrossRefPubMed
41.
Khan FZ, Virdee MS, Palmer CR, Pugh PJ, O’Halloran D, Elsik M, et al. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. J Am Coll Cardiol. 2012;59:1509–18.CrossRefPubMed
42.
Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013;369:1395–405.CrossRefPubMed
43.
Zhou W, Hou X, Piccinelli M, Tang X, Tang L, Cao K, et al. 3D Fusion of LV venous anatomy on fluoroscopy venograms with epicardial surface on SPECT myocardial perfusion images for guiding CRT LV lead placement. J Am Coll Cardiol Img. 2014;7:1239–48.CrossRef
44.
Atchley AE, Iskandrian AE, Bensimhon D, Ellis SJ, Kitzman DW, Shaw LK, et al. HF-ACTION Trial Nuclear Ancillary Study Investigators. Relationship of technetium-99m tetrofosmin-gated rest single-photon emission computed tomography myocardial perfusion imaging to death and hospitalization in heart failure patients: results from the nuclear ancillary study of the HF-ACTION trial. Am Heart J. 2011;161:1038–45.PubMedCentralCrossRefPubMed
45.
AlJaroudi W, Alraies C, Hachamovitch R, Jaber WA, Brunken R, Cerqueira MD, et al. Association of left ventricular mechanical dyssynchrony with survival benefit from revascularization: a study of gated positron emission tomography in patients with ischemic LV dysfunction and narrow QRS. Eur J Nucl Med Mol Imaging. 2012;39:1581–91.CrossRefPubMed
46.
Peix A, Karell J, Rodriguez L, Cabrera LO, Padron K, Carrillo R, et al. Gated SPECT myocardial perfusion imaging, intraventricular synchronism, and cardiac events in heart failure. Clin Nucl Med. 2014;39:498–504.CrossRefPubMed
47.
Haugaa KH, Smedsrud MK, Steen T, Kongsgaard E, Loennechen JP, Skjaerpe T, et al. Mechanical dispersion assessed by myocardial strain in patients after myocardial infarcti.on for risk prediction of ventricular arrhythmia. J Am Coll Cardiol Img. 2010;3:247–56.CrossRef
48.
Murrow J, Esteves F, Galt J, Chen J, Garcia E, Lin J, et al. Characterization of mechanical dyssynchrony measured by gated single photon emission computed tomography phase analysis after acute ST-elevation myocardial infarction. J Nucl Cardiol. 2011;18:912–9.PubMedCentralCrossRefPubMed
49.
Hage FG. Left ventricular mechanical dyssynchrony by phase analysis as a prognostic indicator in heart failure. J Nucl Cardiol. 2014;21:67–70.CrossRefPubMed
50.
Goldberg AS, Alraies MC, Cerqueira MD, Jaber WA, Aljaroudi WA. Prognostic value of left ventricular mechanical dyssynchrony by phase analysis in patients with non-ischemic cardiomyopathy with ejection fraction 35-50% and QRS < 150 ms. J Nucl Cardiol. 2014;21:57–66.CrossRefPubMed
51.
Peix A, Macides A, Rodriguez L, Cabrera LO, Padron K, Heres F, et al. Stress–rest myocardial perfusion scintigraphy and adverse cardiac events in heart failure patients. MEDICC Rev. 2015;17:33–8.PubMed
52.
Hage FG, Aggarwal H, Patel K, Chen J, Jacobson AF, Heo J, et al. The relationship of left ventricular mechanical dyssynchrony and cardiac sympathetic denervation to potential sudden cardiac death events in systolic heart failure. J Nucl Cardiol. 2014;21:78–85.CrossRefPubMed
53.
Chen X, Werner RA, Javadi MS, Maya Y, Decker M, Lapa C, et al. Radionuclide imaging of neurohormonal system of the heart. Theranostics. 2015;5:545–8.PubMedCentralCrossRefPubMed
54.
Fallavollita JA, Heavey BM, Luisi Jr AJ, Michalek SM, Baldwa S, Mashtare Jr TL, et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol. 2014;63:141–9.PubMedCentralCrossRefPubMed
55.•
Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 metaiodobenzylguanidine imaging and cardiac events in heart failure: results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55:2212–21. The ADMIRE-HF demonstrated the capacity of quantitation of sympathetic innervation of the myocardium, measured by the H/M on 123 I-MIBG scintigraphy, for predicting prognosis for significant cardiac events in subjects with HF and significant left ventricular dysfunction, independently of independent of other commonly measured parameters such as LVEF and BNP.
56.
Eckelman WC, Dilsizian V. Chemistry and biology of radiotracers that target changes in sympathetic and parasympathetic nervous systems in heart disease. J Nucl Med. 2015;56:7S–10.CrossRefPubMed
57.
Jacobson AF, Narula J. Introduction to cardiac neuronal imaging: a clinical perspective. J Nucl Med. 2015;56:3S–6.CrossRefPubMed
58.
Nakajima K, Nakata T. Cardiac 123I-MIBG imaging for clinical decision making: 22-year experience in Japan. J Nucl Med. 2015;56:11S–9.CrossRefPubMed
59.
Dimitriu-Leen AC, Scholte AJ, Jacobson AF. 123I-MIBG SPECT for evaluation of patients with heart failure. J Nucl Med. 2015;56:25S–30.CrossRefPubMed
60.
Travin MI. Cardiac radionuclide imaging to assess patients with heart failure. Semin Nucl Med. 2014;44:294–313.CrossRefPubMed
61.
Boogers MJ, Borleffs CJW, Henneman MM, van Bommel RJ, van Ramshorst J, Boersma E, et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol. 2010;55:2769–77.CrossRefPubMed
62.
Rijnierse MT, Allaart CP, de Haan S, Harms HJ, Huisman MC, Wu L, et al. Sympathetic denervation is associated with microvascular dysfunction in non-infarcted myocardium in patients with cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2015;16:788–98.CrossRefPubMed
63.
Al Badarin FJ, Wimmer AP, Kennedy KF, Jacobson AF, Bateman TM. The utility of ADMIRE-HF risk score in predicting serious arrhythmic events in heart failure patients: incremental prognostic benefit of cardiac 123I-mIBG scintigraphy. J Nucl Cardiol. 2014;21:756–62.CrossRefPubMed
64.
Wessler BS, Udelson JE. Neuronal dysfunction and medical therapy in heart failure: can an imaging biomarker help to “personalize” therapy? J Nucl Med. 2015;56:20S–4.CrossRefPubMed
65.
Nakajima K, Okuda K, Yoshimura M, Matsuo S, Wakabayashi H, Imanishi Y, et al. Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera collimator variations. J Nucl Cardiol. 2014;21:970–8.PubMedCentralCrossRefPubMed
66.
Verschure DO, Veltman CE, Manrique A, Somsen GA, Koutelou M, Katsikis A, et al. For what endpoint does myocardial 123I-MIBG scintigraphy have the greatest prognostic value in patients with chronic heart failure? Results of a pooled individual patient data meta-analysis. Eur Heart J Cardiovasc Imaging. 2014;15:996–1003.CrossRefPubMed
67.
Leosco D, Parisi V, Pellegrino T, Pagano G, Femminella GD, Bevilacqua A, et al. Alterations of left ventricular deformation and cardiac sympathetic derangement in patients with systolic heart failure: a 3D speckle tracking echocardiography and cardiac 123I-MIBG study. Eur J Nucl Med Mol Imaging. 2015;42:1601–11.CrossRefPubMed
68.
JCS Joint Working Group. Guidelines for Clinical Use of Cardiac Nuclear Medicine (JCS 2010): digest version. Circ J. 2012;76:761–7.CrossRef
69.
Abdulghani M, Duell J, Smith M, Chen W, Bentzen SM, Asoglu R, et al. Global and regional myocardial innervation before and after ablation of drug-refractory ventricular tachycardia assessed with 123I-MIBG. J Nucl Med. 2015;56:52S–8.CrossRefPubMed
70.
Borgquist R, Singh JP. An electrophysiologist perspective on risk stratification in heart failure: can better understanding of the condition of the cardiac sympathetic nervous system help? J Nucl Med. 2015;56:59S–64.CrossRefPubMed
71.
Zhou Y, Zhou W, Folks RD, Manatunga DN, Jacobson AF, Bax JJ, et al. I-123 MIBG and Tc-99m myocardial SPECT imaging to predict inducibility of ventricular arrhythmia on electrophysiology testing: a retrospective analysis. J Nucl Cardiol. 2014;21:913–20.CrossRefPubMed
72.
Klein T, Abdulghani M, Smith M, Huang R, Asoglu R, Remo BF, et al. Three-dimensional 123I-meta-iodobenzylguanidine cardiac innervation maps to assess substrate and successful ablation sites for ventricular tachycardia: a feasibility study for a novel paradigm of innervation imaging. Circ Arrhythm Electrophysiol. 2015;8:583–91.CrossRefPubMed
73.
Verberne H, Henzlova M, Jain D. 123I-MIBG and 99mTc-tetrofosmin SPECT for prediction of arrhythmic risk in ischemic heart failure patients [abstract]. J Nucl Med. 2014;55 suppl 1:182.
74.
Clements IP, Garcia EV, Folks RD, Butler J, Jacobson AF. Differences in myocardial sympathetic innervation and perfusion in patients with ischemic versus non-ischemic heart failure. J Card Fail. 2014;20(suppl):S17.CrossRef
75.
Clements IP, Garcia EV, Chen J, Folks RD, Butler J, Jacobson AF. Quantitative iodine-123-metaiodobenzylguanidine (MIBG) SPECT imaging in heart failure with left ventricular systolic dysfunction: development and validation of automated procedures in conjunction with technetium-99m tetrofosmin myocardial perfusion SPECT. J Nucl Cardiol. 2015
76.
Gimelli A, Liga R, Giorgetti A, Genovesi D, Marzullo P. Assessment of myocardial adrenergic innervation with a solid-state dedicated cardiac cadmium zinc telluride camera: first clinical experience. Eur Heart J Cardiovasc Imaging. 2014;15:575–85.CrossRefPubMed
Metadata
Title
Nuclear Cardiology in the Management of Patients with Heart Failure
Authors
Amalia Peix
Lázaro O. Cabrera
Kenia Padrón
Publication date
01-01-2016
Publisher
Springer US
Published in
Current Cardiovascular Imaging Reports / Issue 1/2016
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI
https://doi.org/10.1007/s12410-015-9363-8

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits